The following lists resources for an Alliance-wide effort to support iRECIST, a standard for tumor response measurements and definitions on our clinical trials in which an immunotherapy is used.

iRECIST RESOURCES for Alliance trials

• General iRECIST Trainings
• iRECIST Guidelines Article

Alliance Trials Using iRECIST

Active

• Alliance A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Closed

• Alliance A091605: A Randomized Phase II Study of Anti-PD1 Antibody [Pembrolizumab MK-3475] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma